Daniel D’Almeida Preto

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Kim N., Dana E. Rathkopf, Matthew R. Smith et al. · Journal of Clinical Oncology · 2023 · 319 citations · Full text

Medicine, Oncology, Urology +17

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

Fred Saad, Egils Vjaters, Neal D. Shore et al. · Journal of Clinical Oncology · 2024 · 141 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis

Silke Gillessen, Bertrand Tombal, Fabio Turco et al. · European Urology · 2025 · 27 citations · Full text

Medicine, Pharmacotherapy, Radiation Oncology +13

A phase II trial of pembrolizumab plus platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial.

Fernando Cotait Maluf, Karine Martins da Trindade, Daniel D’Almeida Preto et al. · Journal of Clinical Oncology · 2024 · 25 citations · Full text

Medicine, Oncology, Pharmacology +17

Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)

Nizar M. Tannir, Maria Nirvana Formiga, Konstantin Penkov et al. · Journal of Clinical Oncology · 2024 · 24 citations

Medicine, Immunology, Oncology +17